In patients with renal cell carcinoma (RCC), around 20% demonstrate non-clear cell (nccRCC) histology, including various histological types. The role of cytoreductive nephrectomy (CN) for patients with metastatic nccRCC is currently undetermined, with surgery persisting as a major option for those with localized stage nccRCC. A study from Ondřej Fiala, MD, PhD, and colleagues sought to determine the effects of upfront CN on outcomes for patients with metastatic nccRCC who received first-line immune checkpoint inhibitor (immunotherapy [IO]) combinations or tyrosine kinase inhibitor (TKI) monotherapy. ...
nccRCC
Advertisement
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
The investigators found significant differences in OS and recurrence-free survival across the histological subtypes.
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Researchers noted that following first-line TKI therapy, effective subsequent treatment options for nccRCC were unclear.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
While advances have improved understanding of molecular targets, optimal management of nccRCC remains unclear.
Advertisement
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Latest News
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
